Background
Older adults with cancer are at increased risk of treatment‐related toxicities and excess mortality. We evaluated whether a patient‐reported geriatric assessment (GA) based frailty index can identify those at risk of adverse outcomes.
Methods
Older adults (≥60 years) enrolled in a single‐institutional prospective registry underwent patient‐reported GA at initial evaluation in our medical oncology clinic. Using deficit accumulation method, we constructed a 44‐item frailty index (CARE‐FI), categorizing patients as robust, pre‐frail, and frail. The primary outcome was overall survival (OS). Secondary outcomes included (a) functional decline at 3 months post‐therapy (b) incident grade ≥3 treatment‐related toxicities at six‐month post‐treatment. We used multivariate Cox and logistic regression models respectively to study the impact of frailty on primary and secondary outcomes.
Results
We identified 589 older adults with a median age of 69 years; 55% males and 73% Whites. Overall, 168 (29%) were pre‐frail and 230 (39%) frail. Being frail (vs. robust) was associated with worse OS (Hazards Ratio, HR 1.83, 95% Confidence Interval, CI 1.34–2.49, p < 0.001) after adjusting for age, sex, race/ethnicity, cancer type, cancer stage, and line of therapy. Similarly, frailty was associated with increased risk of functional decline (OR 3.01; 95% CI 1.33–6.81; p = 0.008) and grade ≥3 non‐hematologic toxicities (OR 3.65; 95% CI 1.54–8.69; p = 0.003) but not hematologic toxicities (OR 1.01; 95% CI 0.46–2.22; p = 0.97).
Conclusions
Our frailty index using a patient‐reported GA is a robust predictor of survival, functional decline, and treatment related toxicity among older adults with GI malignancies.